Enzyme-Based Scissors Target Cancer Cell Defenses: Researchers at Stanford University Reveal

The biomolecule's ability to degrade mucins on cancer cells represents a significant advancement in the fight against cancer, offering new avenues for effective and targeted treatment options.

In a groundbreaking discovery, researchers at Stanford University have engineered a remarkable biomolecule that could revolutionize cancer treatment. This newly developed biomolecule acts like a pair of scissors, specifically cutting away sugar-coated proteins known as mucins from cancer cells. By stripping these mucins, the biomolecule exposes cancer cells to the immune system, potentially paving the way for more effective cancer therapies.


Mucins are normally beneficial proteins coated with sugar molecules, serving as the body's defense against physical harm and pathogens. However, cancer cells have found a way to exploit mucins, using them as a shield against the immune system. Removing mucins from cancer cells could be a potential strategy for cancer therapy. However, since mucins are present in various forms throughout the body, targeting them without precision might have unintended consequences.


The solution devised by the Stanford-led research team involves creating an enzyme-based scissors. This unique biomolecule combines a mucin-cutting enzyme called mucinase with a cancer-cell-targeting nanobody, a fragment of an antibody. Together, these components selectively target and remove mucins from specific cancer cells.


The study's results, published in Nature Biotechnology, demonstrated the biomolecule's potential. In lab-grown human cancer cells and simulated mouse studies of breast and lung cancer, the biomolecule treatment significantly reduced tumor growth and improved survival rates. This breakthrough has far-reaching implications, as mucins are associated with a range of diseases beyond cancer, including respiratory conditions and viruses.


Senior author Carolyn Bertozzi, a respected figure in the field, explained the significance of their findings. "We found that we could target this mucinase to cancer cells, use it to remove mucins from those cancer cells, and there was a therapeutic benefit," she stated.


The co-lead author of the study, Gabrielle Tender, along with former members of Bertozzi's lab, Kayvon Pedram and D. Judy Shon, collaborated to develop this innovative approach.


Mucins, while usually beneficial, can contribute to cancer progression when misused by cancer cells. One function involves helping cancer cells survive in environments where they are not firmly attached. Additionally, cancer cells can employ mucins to bind to immune system checkpoint receptors, avoiding detection and immune response.


The biomolecule designed by the research team is a fusion of two parts. The first part, the mucinase, cleaves mucins, while the second part, a cancer-specific nanobody, targets cancer cells. This nanobody guides the mucinase to cancer cells, ensuring that it only removes mucins from these cells.


The study's success brings us one step closer to potential new cancer therapies. The next challenge is to develop a human-derived mucinase, as the current version is not human-derived and may trigger unwanted immune responses.

While more research is needed before this approach can be implemented in clinical settings, this breakthrough holds immense promise. The biomolecule's ability to degrade mucins on cancer cells represents a significant advancement in the fight against cancer, offering new avenues for effective and targeted treatment options.

Tags : #StanfordUniversity #Mucins #biomolecule #advancement #NatureBiotechnology

About the Author

Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...


Trending Now

Rare H9N2 Bird Flu Case Found in Four-Year-Old in India: WHO Highlights Ongoing RisksJune 15, 2024
Kerala Government Announces Aid Package After Kuwait Fire TragedyJune 15, 2024
EV Conference 24---Charging Up for e-mobility Minister Ponnam Prabhakar and Jayesh Ranjan among others to graceJune 14, 2024
Are we on track to end AIDS, end viral hepatitis and end STIs by 2030?June 14, 2024
HR Conclave Focusing on Future-Forward Engineering where Engineering and Management students meet their future employees, thus exposing students to real-world HR challenges and innovative solutionsJune 14, 2024
MAGGI Empowers 10 Women to Bring their Entrepreneurial dreams to lifeJune 13, 2024
FTCCI announced its Annual Excellence Awards and invites entries, last date is 20th June 2024June 13, 2024
Bird Flu Cases by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.June 13, 2024
Sova Health's $1 Million Seed Funding to Drive Gut Health InnovationJune 13, 2024
The Vital Role of Early Detection: Kevin Jonas on Battling Skin CancerJune 13, 2024
Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 AntibodyJune 13, 2024
HP Ghosh Hospital Unveils Innovative "Chest Tree" June 12, 2024
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, IndiaJune 12, 2024
From the frontlines: Homeless person won over alcoholism, survived floods and defeated TBJune 12, 2024
The Role of Hormones in Obesity: Why Men and Women Gain Weight DifferentlyJune 12, 2024
Silent Killer: How a Young Mother’s Vision Loss Led to a Lung Cancer DiagnosisJune 12, 2024
TruAlt Bioenergy’s subsidiary, Leafiniti Bioenergy supplies over 1000 tons of Compressed Biogas to AG&P Pratham in just 5 monthsJune 11, 2024
Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in SingaporeJune 11, 2024
Poor Muscle Health in Obesity Can be A Major Risk Factor for Early DeathJune 11, 2024
Machine Learning Uncovers How Organ Ageing Impacts Health and LongevityJune 11, 2024